Apomorphine in Severe Brain-injured Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Disorder of Consciousness
Interventions
DRUG

Apomorphine Hydrochloride 5mg/ml

Product administered using an external continuous subcutaneous infusion pump.

OTHER

Sodium chloride 9mg/ml

Product administered using an external continuous subcutaneous infusion pump.

Trial Locations (4)

1340

RECRUITING

Centre Hospitalier Neurologique William Lennox, Ottignies-Louvain-la-Neuve

4000

ACTIVE_NOT_RECRUITING

University of Liege, Liège

RECRUITING

Hôpital Valdor - ISoSL, Liège

46035

NOT_YET_RECRUITING

VITHAS, Valencia

All Listed Sponsors
collaborator

Centre Hospitalier Neurologique William Lennox (Belgium)

UNKNOWN

collaborator

Hôpital Valdor - ISoSL (Belgium)

UNKNOWN

collaborator

VITHAS hospitales (Spain)

UNKNOWN

lead

University of Liege

OTHER

NCT05213169 - Apomorphine in Severe Brain-injured Patients | Biotech Hunter | Biotech Hunter